BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical ...

Praxis Precision Medicines has been blindsided by a recommendation to stop a phase 3 essential tremor trial. Two months after ...

Richard Heinberg, a senior fellow with the Post Carbon Institute in Santa Rosa, will be the featured speaker at a weekend ...

Praxis Precision Medicines said an independent committee had recommended stopping a late-stage trial of an experimental drug for a movement disorder as it was unlikely to meet the main goal, sending ...

Praxis' epilepsy pipeline takes center stage after Ulixacaltamide's Phase 3 futility. Key trials for vormatrigine and ...

Financially stable with $469.5 million in cash, Praxis Precision Medicines can fund operations until 2028. Read why my rating ...

US-based Praxis Precision has decided not to halt its Phase III trial examining its essential tremor (ET) therapy after an ...

BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage ...

Praxis Precision Medicines said on Friday an independent committee had recommended that its tremor drug trial be stopped for futility, as the trial was unlikely to meet the main goal. Shares of the ...

Praxis on Friday said the independent data monitoring committee overseeing an interim analysis of Study 1 of the "Essential3" program has recommended that the study be stopped for futility because it ...

Praxis Precision Medicines shares lost more than a third of their value on Friday after the clinical-stage biopharmaceutical company suffered a setback in its late-stage studies of its ulixacaltamide ...

Early results were shared during the Praxis scientific exhibit at the December 2024 American Epilepsy Society Annual Meeting, demonstrating significant disease burden compounded by persistent, ...